Diagnostics & testing
FIND and The Global Fund are co-conveners of the Access to COVID-19 Tools (ACT) Accelerator Diagnostics Pillar. The ACT-Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. It was set up in response to a call from G20 leaders in March and launched by the WHO, the European Commission, France and the Bill & Melinda Gates Foundation in April 2020.
This diagnostics resource centre provides information, updates and progress on tests and testing, in support of the agenda set out in the ACT-Accelerator Diagnostics Pillar investment case.
Call to action: global crisis on testing
Testing is vital to save lives today, to develop and deploy vaccines and effective treatments without delay, to protect healthcare workers and strengthen health systems against future threats, to inform the safe reopening of economies, and to protect the global health gains of recent decades.
The window of opportunity to invest in and ramp up testing is closing. Missing this opportunity may lead to delays in vaccine and treatment roll out, excessive spending on healthcare, and greater economic losses due to unnecessary lockdowns.
Expressions of interest: antigen RDTs
Call for expressions of interest (EOI) now open to accelerate the availability and manufacturing scale-up of rapid diagnostic tests for the detection of SARS-CoV-2 antigens.
Innovators, RDT developers, IVD manufacturers and LMIC-based diagnostic stakeholders are invited to apply. A range of funding mechanisms could be applied according to the needs of each business case.
We are continually updating our searchable database showing the current status of SARS-CoV-2 tests in development and commercialized.
Independent test evaluations
We are conducting independent evaluations of molecular tests and immunoassays, in collaboration with WHO and multiple partners worldwide, to assist in-country decision making.
We are collating and centralizing performance data on commercially available in vitro diagnostic tests for SARS-CoV-2 as a global public good.
Using rapid diagnostic tests for COVID-19
Understand more about rapid diagnostic tests for COVID-19 – how they work, benefits of using different tests in different scenarios, and interpretation of results.
Current testing situation worldwide
Our interactive map tracks the number of SARS-CoV-2 tests reported to have been performed in each country, and compares it with the number that showed a positive result, to build a picture of how many people in the world are being tested for COVID-19.
Diagnostics implementation simulator
Discover our Diagnostic Implementation Simulator for SARS-CoV-2 diagnostics, developed in partnership with the EPFL Blue Brain Project and Ateneo de Manila University. It uses modeling data to simulate scenarios and estimate the potential impact of deploying different testing strategies for COVID-19.
COVID-19 diagnostics and testing
Join over 16,000 learners from 186 countries and sign up for the free online training course we have developed in partnership with ASLM and LSHTM, hosted by FutureLearn. The second run of the 3-week course launched on 15 June 2020 and will be available for 5 weeks. The French version of the online training launched on 20 July 2020 and has been developed in partnership with Fondation Mérieux. These courses can be followed at your own pace and is designed for Ministry of Health officials, laboratory professionals, clinicians and anyone involved in laboratory testing and diagnosis for COVID-19, with a focus on low- and-middle-income settings.